Prevention of Postpartum Hemorrhage with Oxytocin versus Ergometrine Plus Oxytocin in the third stage of labor

Not Applicable

Completed

• Conditions: Postpartum blood lossPostpartum haemorrhageNeed for additional uterotonic drugsNeed for blood transfusionChanges in hemoglobin level after deliverySide effects; Blood loss, PPH, ergometrine, oxytocin, prevention, adverse effects

• Registration Number: TCTR20150820001
• Lead Sponsor: Vajira Institutional Review Board

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2015-01-31
• Study Start: 2015-08-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 323

Inclusion Criteria

singleton pregnancy at >28 weeks of gestation,
cephalic presentation,
anticipating a normal spontaneous vaginal delivery

Exclusion Criteria

non -cephalic presentation, multiple pregnancies, polyhydramnios, uterine fibroids, previous postpartum hemorrhage, antepartum hemorrhage, parity greater than four, previous cesarean section, severe anemia (hemoglobin level of ≤ 8 g/dL), coagulopathy, contraindications to the use of ergometrine, estimated fetal birth weight >4000 g, inability to obtain written consent, cesarean section, instrumental delivery

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Postpartum blood loss postpartum blood collection (ml)

Secondary Outcome Measures

Name	Time	Method
PPH, side effect ,need for additional uterotonic drugs need for blood transfusion Changes in hemogl postpartum